| pubmed-article:3742157 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C0999699 | lld:lifeskim |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C0026820 | lld:lifeskim |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C0029144 | lld:lifeskim |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C0027358 | lld:lifeskim |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C0205409 | lld:lifeskim |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C0022203 | lld:lifeskim |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C0376249 | lld:lifeskim |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C0001272 | lld:lifeskim |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C0441722 | lld:lifeskim |
| pubmed-article:3742157 | lifeskim:mentions | umls-concept:C1521827 | lld:lifeskim |
| pubmed-article:3742157 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:3742157 | pubmed:dateCreated | 1986-10-8 | lld:pubmed |
| pubmed-article:3742157 | pubmed:abstractText | Naloxone in concentrations ranging from 7.5 to 120 mumol l-1 reduced the beating frequency of guinea-pig isolated atria. The ED50 was 7.9 mumol l-1 for the (-)-isomer and 10.8 mumol l-1 for the (+)-isomer. Concentrations up to 120 mumol l-1 of either (-)- or (+)-naloxone did not affect the force of contraction of left atria stimulated at 1 Hz. In concentrations from 30 to 120 mumol l-1 (-)-naloxone increased the action potential (AP) duration and the functional refractory period (FRP) of papillary muscles. The resting membrane potential and the AP amplitude remained unchanged, while a small decrease of Vmax was seen with the larger drug concentrations. The influence of (+)-naloxone (120 mumol l-1) was comparable to that of the (-)-isomer. The influence of morphine (120 mumol l-1) on papillary muscle AP was small. AP duration and FRP showed a marginal prolongation while Vmax was slightly decreased. (-)-Naloxone 60 mumol l-1 had no effect on slow-response APs of K+-depolarized papillary muscles. Slow-response APs were abolished by verapamil (1 mumol l-1). In left atrial strips the prolongation of the AP duration produced by 120 mumol l-1 of either (-)- or (+)-naloxone resembled the drug effect in papillary muscles. Most of the observed changes can be explained by an inhibition of the time-dependent membrane K+ outward current, an effect of naloxone that may be classified as a Class III antiarrhythmic action. Apparently this effect is not mediated by stereospecific opioid receptors. | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3742157 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3742157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3742157 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3742157 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:3742157 | pubmed:issn | 0007-1188 | lld:pubmed |
| pubmed-article:3742157 | pubmed:author | pubmed-author:BraschHH | lld:pubmed |
| pubmed-article:3742157 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3742157 | pubmed:volume | 88 | lld:pubmed |
| pubmed-article:3742157 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3742157 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3742157 | pubmed:pagination | 733-40 | lld:pubmed |
| pubmed-article:3742157 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:meshHeading | pubmed-meshheading:3742157-... | lld:pubmed |
| pubmed-article:3742157 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3742157 | pubmed:articleTitle | Influence of the optical isomers (+)- and (-)-naloxone on beating frequency, contractile force and action potentials of guinea-pig isolated cardiac preparations. | lld:pubmed |
| pubmed-article:3742157 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3742157 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3742157 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3742157 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3742157 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3742157 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3742157 | lld:pubmed |
